Last reviewed · How we verify
Clinique des Céphalées de Montréal — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Agomab Spain S.L. · 1 shared drug class
- Avalo Therapeutics, Inc. · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- Celltrion · 1 shared drug class
- Centocor, Inc. · 1 shared drug class
- Dermira, Inc. · 1 shared drug class
- European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
- Gliknik Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Clinique des Céphalées de Montréal:
- Clinique des Céphalées de Montréal pipeline updates — RSS
- Clinique des Céphalées de Montréal pipeline updates — Atom
- Clinique des Céphalées de Montréal pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Clinique des Céphalées de Montréal — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clinique-des-c-phal-es-de-montr-al. Accessed 2026-05-18.